A perfused human blood-brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport.

Wevers NR, Kasi DG, Gray T, Wilschut KJ, Smith B, van Vught R, Shimizu F, Sano Y, Kanda T, Marsh G, Trietsch SJ, Vulto P, Lanz HL, Obermeier B. · 2018

Read A perfused human blood-brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport. by Wevers NR, Kasi DG, Gray T, Wilschut KJ, Smith B, van Vught R, Shimizu F, Sano Y, Kanda T, Marsh G, Trietsch SJ, Vulto P, Lanz HL, Obermeier B. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6117964.txt.

Introduction

Wevers and co-authors present a methods article in Fluids and Barriers of the CNS on a human blood-brain barrier built on a chip. The barrier guards the brain from most large drugs. Testing whether antibody drugs cross it is slow work. The team built a tiny, flowing model of the barrier for high-throughput tests.

The chips hold human brain vessel cells with astrocytes and pericytes. Up to 96 chips fit in one plate. The model formed tight seals and blocked a dye well. An antibody aimed at the transferrin receptor crossed more than a control antibody. The authors say the setup suits drug screening work.

Catalog record

CREATORWevers NR, Kasi DG, Gray T, Wilschut KJ, Smith B, van Vught R, Shimizu F, Sano Y, Kanda T, Marsh G, Trietsch SJ, Vulto P, Lanz HL, Obermeier B.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE54 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6117964

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

A perfused human blood–brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport By Nienke R. Wevers, Dhanesh G. Kasi, Taylor Gray, Karlijn J. Wilschut, Benjamin Smith, Remko van Vught, Fumitaka Shimizu, Yasuteru Sano, Takashi Kanda, Graham Marsh, Sebastiaan J. Trietsch, Paul Vulto Published in: Fluids and Barriers of the CNS DOI: 10.1186/s12987-018-0108-3 ABSTRACT Background Receptor-mediated transcytosis is one of the major routes for drug delivery of large molecules into the brain. The aim of this study was to develop a novel model of the human blood–brain barrier (BBB) in a high-throughput microfluidic device. This model can be used to assess passage of large biopharmaceuticals, such as therapeutic antibodies, across the BBB. Methods The model comprises human cell lines of brain endothelial cells, astrocytes, and pericytes in a two-lane or three-lane microfluidic platform that harbors 96 or 40 chips, respectively, in a 384-well plate format. In each chip, a perfused vessel of brain endothelial cells was grown against an extracellular matrix gel, which was patterned by means of surface tension techniques. Astrocytes and pericytes were added on the other side of the gel to complete the BBB on-a-chip model. Barrier function of the model was studied using fluorescent barrier integrity assays. To test antibody transcytosis, the lumen of the model’s endothelial vessel was perfused with an anti-transferrin receptor antibody or with a control antibody. The levels of antibody that penetrated to the basal compartment were quantified using a mesoscale discovery assay. Results The perfused BBB on-a-chip model shows presence of adherens and tight junctions and severely limits the passage of a 20 kDa FITC-dextran dye. Penetration of the antibody targeting the human transferrin receptor (MEM-189) was markedly higher than penetration of the control antibody (apparent permeability of 2.9 × 10−5 versus 1.6 × 10−5 cm/min, respectively). Conclusions We demonstrate successful integration of a human BBB microfluidic model in a high-throughput plate-based format that can be used for drug screening purposes. This in vitro model shows sufficient barrier function to study the passage of large molecules and is sensitive to differences in antibody penetration, which could support discovery and engineering of BBB-shuttle technologies. Electronic supplementary material The online version of this article (10.1186/s12987-018-0108-3) contains supplementary material, which is available to authorized users. BACKGROUND The blood–brain barrier (BBB) ensures a homeostatic environment for the central nervous system (CNS) and is essential for healthy brain functioning. The BBB comprises specialized endothelial cells and supporting cells, such as astrocytes and pericytes. Due to a combination of specific transport mechanisms and the presence of adherens junctions and tight junctions, the BBB controls passage of compounds into the brain [1–5]. This way, the BBB protects the brain from many harmful substances that circulate in the blood. However, the BBB’s barrier properties also complicate the treatment of CNS disorders, as many small- and large-molecule pharmaceuticals are restricted from entering the brain in quantities that are large enough to elicit a therapeutic response [6]. It is therefore necessary to develop improved drug delivery strategies that enable efficient delivery of biopharmaceuticals to the brain. The BBB employs specialized transporter systems to allow essential nutrients to enter the brain. The transport system that is most attractive to deliver large-molecule drugs into the brain is receptor-mediated transcytosis (RMT). In RMT, a ligand (or antibody) binds a receptor on the luminal surface of a brain endothelial cell, after which it undergoes internalization via endocytosis and is trafficked to the abluminal side, where it can be released and gain access to the brain parenchyma. Harnessing this process for therapeutic drug delivery is compelling, as it could allow for selective transport into the CNS in a non-invasive manner, without disruption of the BBB [7, 8]. Several studies have demonstrated increased CNS exposure to therapeutic antibodies by combining them with RMT targeting antibodies against the transferrin receptor, insulin receptor, low-density lipoprotein receptor-related proteins 1 and 2, and the large neutral amino acid transporter 1 [9–11]. However, challenges exist in optimizing antibody properties (such as affinity, valency, bispecific format, and Fc receptor engagement) to effectively and safely traffic across the brain endothelium [12–16]. Improved in vitro models that enable further research of the cellular and molecular mechanisms underlying transcytosis at the BBB are needed to improve these CNS drug delivery technologies [14, 17, 18]. While in vivo models can be used to study an intact BBB in its physiological environment, the complexity involved in deciphering whole-organism drug distribution and the lower throughput of these studies limits their use in screening for BBB-penetrant antibodies. For this reason, in vivo research in the field is complemented by simpler and faster in vitro models, such as the Transwell method [19–22] and several on-a-chip systems [23–29]. Although the field of in vitro BBB modelling has tremendously progressed in recent years, there is a need for a model that combines fast, high-throughput readouts with physiologically relevant conditions, such as flow, co-culture, and the absence of artificial membranes. In this manuscript, we show the development of an in vitro model of the human BBB in a high-throughput microfluidic platform. The platform allows patterning of extracellular matrix gel by means of surface tension. A blood vessel is grown adjacent to that gel and a third channel is used to insert astrocytes and pericytes. The system is free of artificial membranes, accommodates fluid flow through the blood vessels, and allows fluid-phase sampling of molecules that penetrate the endothelial and matrix layers. Using two different antibodies, we show that the model is sensitive to differences in antibody penetration of brain endothelial cells. The model may support further discovery of antibody BBB-shuttle technologies. METHODS Cell culture Cell lines of brain endothelial cells, pericytes, and astrocytes were provided by Yamaguchi University, Japan, and originate from the following human primary cell sources: human brain microvascular endothelial cells (TY10 cell line) were isolated from normal brain tissue from a patient with meningioma. Human brain pericytes (hBPCT cell line) were derived from brain tissue of a patient that died from a heart attack. Human astrocytes (hAst cell line) were generated from human primary astrocytes distributed by Lonza (Basel, Switzerland). All three cell types were immortalized with retroviral vectors harboring a SV40 large T antigen gene that is engineered to drive proliferation at 33 °C [30–34] and have been used to model the BBB in previous studies [35–38]. Cells were cultured at 33 °C, 5% CO2 to allow optimal cell expansion in T75 flasks (734-2705, Corning, NY, USA), which were pre-coated with 50 µg/mL collagen-I (Cultrex 3D collagen-I Rat Tail, 5 mg/mL, 3447-020-01, AMSbio, Abingdon, UK) in 1% acetic acid (A6283, Sigma, St. Louis, MO, USA) in water. TY10 cells were used between passage 17–25 and cultured in ScienCell endothelial cell medium (#1001, Sciencell, Carlsbad, CA, USA). The hAst cells were used between passage 7–12 and cultured in ScienCell astrocyte medium (#1018, Sciencell). The hBPCT cells were used between passage 14–25 and cultured in ScienCell pericyte medium (#1012, Sciencell). Cells were routinely tested for mycoplasma contamination and found negative. Culture of TY10 microvessels in the two-lane OrganoPlate Two-lane OrganoPlates (Mimetas BV, the Netherlands) with 400 µm × 220 µm (w × h) channels were employed. Phaseguides had dimensions of 100 µm × 55 µm (w × h) and 2

Read the complete text